1. Introduction

Biotechnology patent filing in Australia is governed principally by the Patents Act 1990 (Cth), the Patents Regulations 1991, and the administrative and examination procedures of IP Australia. These laws establish how biotechnology inventions are filed, assessed, published, opposed, and ultimately granted patent protection.

Biotechnology patents can protect qualifying inventions involving genetic engineering, recombinant proteins, microorganisms, cell lines, industrial enzymes, biotechnological manufacturing processes, and certain modified plants and animals. However, discovering a naturally occurring biological material is not automatically equivalent to inventing a patentable product. The invention must satisfy the applicable statutory criteria and disclosure requirements.

IP Australia+1

The principal statutory framework is the Patents Act 1990, especially sections 18, 40, 43, 49 and 101, together with the applicable regulations. These provisions address patentability, the contents of specifications, priority, acceptance and opposition, and amendment.

2. What biotechnology inventions can be patented?

DNA Cloning : Vectors

A. Genetic engineering and recombinant DNA

Examples include engineered microorganisms, recombinant expression systems, genetically modified cells, and synthetic nucleic acid sequences that meet Australian patentability requirements.

LAL Test for Medical Device - STEMart

B. Microorganisms and biological materials

Qualifying isolated or technically produced microorganisms, fungi, cell lines, plasmids, viruses, proteins and enzymes may be patentable.

Superdex™ 75 Increase, Superdex 200 Increase, Superose™ 6 Increase | Chromatography systems | Cytiva

C. Biopharmaceuticals and manufacturing processes

Examples include engineered therapeutic proteins, vaccine-related technologies, fermentation methods and processes for producing or purifying biological compounds.

Plant Biotechnology #13 by Science Photo Library

D. Agricultural biotechnology

Qualifying genetically modified plants, plant cells, and methods of genetic transformation may be protected, subject to the applicable statutory requirements.

IP Australia distinguishes eligible biological inventions from discoveries of biological material in its natural state. A patent specification must identify a practical use and describe the invention sufficiently for a skilled person to reproduce it. Naturally occurring human gene sequences that merely replicate genetic information in the genome of a human or other organism are not patentable under Australia's current approach.

IP Australia+1

3. Essential legal requirements for a biotechnology patent

Section 18 of the Patents Act 1990 sets out the principal patentability criteria for standard patents.

These requirements are assessed claim by claim. A broad claim covering an entire class of genes, proteins or therapeutic uses may encounter problems if the evidence supports only a narrow embodiment or a particular application. The statutory framework and IP Australia's examination guidance are therefore central to biotech patent strategy.

Federal Register of Legislation+1

4. Step-by-step procedure for filing a biotechnology patent in Australia

The application is made through IP Australia. A standard patent is generally the appropriate route for commercially significant biotechnology inventions.

Step 1 — Establish confidentiality and ownership

Identify the inventors, confirm who owns the invention, and review employment agreements, university policies, research collaboration agreements and funding terms. Avoid publishing research, presenting at conferences or disclosing sequences to potential partners before filing.

Step 2 — Conduct a prior-art search

Search Australian and international patent databases, scientific publications, clinical literature, sequence databases and earlier patent applications. The purpose is to identify potentially relevant disclosures and assess novelty and inventive step.

Step 3 — Choose the application route

File a provisional application if further development is needed and the invention can already be adequately described. Alternatively, file a complete standard application or enter the Australian national phase of a Patent Cooperation Treaty (PCT) application.

Step 4 — Draft the patent specification

Describe the biological material, technical problem, experimental methods, results, examples, practical utility and proposed claims. Include relevant sequence listings and drawings. Address enablement, claim support and the best method known of performing the invention.

Step 5 — Make the biological deposit if required

If the invention depends on a microorganism that cannot be adequately described in writing and is not otherwise reasonably available, consider the deposit requirements under section 41 and the applicable regulations. Use a prescribed depository institution and meet the applicable timing and documentation requirements.

Step 6 — File the application and establish priority

Submit the prescribed request and specification to IP Australia, pay the relevant fee, and retain the filing acknowledgement. If claiming priority from an earlier application, ensure that the priority claim is valid and that the earlier application adequately supports the relevant subject matter.

Step 7 — Publication and examination

The application is generally published around 18 months from the relevant priority date. Request examination and respond to objections on patentability, sufficiency, clarity, claim scope and other statutory issues.

Step 8 — Acceptance, opposition and grant

If the application satisfies the requirements, IP Australia accepts it and advertises the acceptance. Third parties ordinarily have three months to oppose. If the application proceeds successfully, the patent is granted and renewal fees must be paid.

This sequence reflects IP Australia's published application procedure and the statutory rules governing patent requests, specifications, microorganism deposits and examination.

IP Australia+2

5. Provisional, standard and PCT applications

A provisional application is not itself an enforceable patent. It does not automatically protect later-added material: new subject matter may receive a later priority date, so a technically thin provisional filing can undermine the eventual claim scope.

IP Australia+2

Important biotech drafting issue: priority and experimental evidence

Suppose a research team files a provisional specification describing a proposed engineered enzyme but provides no workable sequence, no reproducible production method and no evidence supporting the asserted function. If the complete application later introduces those details, the applicant cannot simply assume that every later claim benefits from the provisional date.

A sound filing strategy should describe the invention at a level that supports the intended claims, including representative embodiments, alternatives, working examples and evidence for the asserted technical effect.

6. Biological deposits and sequence disclosures

Biotechnology inventions create special disclosure problems because certain materials cannot be fully reproduced from a written description alone.

A. Microorganism deposits

Section 41 of the Patents Act 1990 provides a mechanism under which specified deposit requirements can satisfy the disclosure requirement for an invention involving a microorganism. The applicable deposit must be made with a prescribed institution under the relevant rules.

The applicant should verify:

Whether a deposit is necessary for a skilled person to reproduce the invention.

Whether the selected institution and deposit date satisfy Australian requirements.

Whether the specification identifies the material and relevant deposit details.

Whether access and availability requirements are satisfied at the relevant stages.

A deposit is not a substitute for explaining the invention's technical features, practical use and claim scope.

Federal Register of Legislation+1

B. DNA and protein sequence listings

For inventions involving nucleic acids or proteins, the specification may need a compliant sequence listing, depending on the application and the applicable formal requirements.

Good practice includes identifying sequences consistently, linking them to the relevant examples and claims, and describing the functional significance of mutations or modifications. A sequence listing alone does not prove novelty, inventive step, utility or patentable subject matter.

C. Enablement and best method

Section 40(2) requires a complete specification to disclose the invention clearly and completely enough for a skilled person to perform it, disclose the best method known to the applicant of performing it, and contain clear, succinct claims supported by the specification.

For example, a claim to a genetically modified microorganism that produces a therapeutic protein may require disclosure of the relevant construct, host, transformation or expression method, and conditions needed to reproduce the claimed result. The level of detail depends on the invention and the scope claimed.

Federal Register of Legislation+1

7. Examination, objections and deadlines

Once a complete standard application has been filed, the applicant must manage several important procedural deadlines.

IP Australia's published guidance explains the examination and opposition stages. Failure to resolve examination objections in time can cause an application to lapse, while opposition can delay or prevent grant.

IP Australia+3

Typical examination objections in biotechnology

Lack of novelty: an earlier patent or scientific publication already discloses the claimed invention.

Lack of inventive step: the claimed modification or process would have been obvious under the applicable legal test.

Insufficient disclosure: the application does not teach a skilled person how to reproduce the claimed invention.

Lack of support: broad claims extend beyond what the specification adequately describes.

Patentable-subject-matter objection: the claim concerns subject matter that does not qualify as a manner of manufacture.

Utility concerns: the claimed invention lacks the required practical usefulness.

An applicant can respond with legal arguments and permissible amendments to the claims. Amendments must comply with statutory restrictions; they cannot simply introduce unsupported new technical matter after filing.

IP Australia+1

8. Important Australian case laws

Australian courts have established principles that are particularly relevant to biotechnology patent applications. The following decisions illustrate how those principles affect filing strategy, patent drafting and validity.

Case 1: D'Arcy v Myriad Genetics Inc [2015] HCA 35

High Court of Australia

Facts: Myriad Genetics held Australian patent claims relating to isolated nucleic acids associated with BRCA1 mutations and susceptibility to breast and ovarian cancer. Yvonne D'Arcy challenged the patent claims.

Issue: Whether the claimed isolated nucleic acids constituted patentable subject matter under section 18(1)(a) of the Patents Act 1990.

Decision: The High Court unanimously allowed the appeal and held that the challenged claims were not patentable inventions. Although the nucleic acids had been isolated, the essential element of the claimed invention was the genetic information embodied in naturally occurring sequences. The Court considered that extending patentability to that claimed subject matter was not justified.

High Court of Australia+1

Legal principle: Merely isolating naturally occurring genetic material does not necessarily make the claimed invention a patentable manner of manufacture.

Practical significance: Applicants should distinguish a discovery of natural genetic information from a genuinely engineered product, a technically developed process, or a specific practical application that satisfies the statutory requirements.

This decision is particularly important when drafting claims involving genes, mutations, nucleic acid sequences and genetic diagnostic technologies.

Case 2: National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252

Facts and issue: This landmark decision concerned whether a process for using chemical substances to control weeds could qualify as a patentable invention under the traditional concept of a manner of manufacture.

Decision: The High Court adopted a practical approach to patentable subject matter, examining whether the invention produced an artificially created state of affairs of economic significance rather than relying on narrow, historical categories of invention.

Legal principle: Patentable subject matter is assessed by considering the substance and practical character of the claimed invention.

Application to biotechnology: A technically developed process for producing a useful biological compound, modifying a microorganism, or performing a defined industrial process may be more readily distinguished from a mere discovery of a natural phenomenon.

However, NRDC does not override statutory exclusions or the later High Court decision in Myriad. A claim must still satisfy all the applicable requirements of patentability.

Case 3: D'Arcy v Myriad Genetics Inc [2014] FCAFC 115

Court: Full Court of the Federal Court of Australia.

Facts: Before the High Court appeal, the Full Court considered whether isolated nucleic acids associated with BRCA1 mutations constituted patentable subject matter.

Decision: The Full Court rejected the challenge and concluded that the claims involved patentable subject matter. It reasoned that the isolated nucleic acids differed chemically and functionally from those occurring within human cells and could be used for the specified diagnostic comparison.

Legal significance: This decision illustrates the earlier judicial approach to isolated genetic material. However, it was overturned by the High Court in 2015 on the challenged claims. It should therefore not be relied upon as the final statement of Australian law on those claims.

High Court of Australia+1

Case 4: Sanofi v Commissioner of Patents (1982) 42 ALR 93

This decision is commonly discussed in connection with the Australian approach to patentable subject matter and the principles associated with NRDC.

Legal relevance: Patentability requires analysis of the substance of the claimed invention and whether it falls within the legal concept of a manner of manufacture.

Application to biotechnology: Applicants should define the actual technical invention—such as a modified biological composition or a reproducible production process—rather than relying solely on the commercial value of a discovery.

The case should be read alongside the statutory requirements and Myriad, particularly where the claims concern biological material derived from nature.

Note: The leading cases above address different aspects of patentable subject matter. They do not replace the separate tests for novelty, inventive step, usefulness and sufficiency.

9. International biotechnology patent filing

Australian applicants often seek patent protection in other jurisdictions because biotechnology products and research markets are international.

A common strategy is:

File an Australian provisional application with an adequately supported description.

Develop the invention and generate further experimental data.

Within 12 months, file a complete application and/or a PCT application claiming priority where appropriate.

Enter the national phase in countries of commercial interest within the applicable deadlines.

Adapt the claims to the patentability rules of each jurisdiction.

The PCT route does not produce a single worldwide patent. Patent rights are ultimately determined through national or regional procedures.

An important strategic consideration is that Australia's grace period for certain public disclosures is generally 12 months, but other jurisdictions may apply different rules. Filing before publication is therefore safer when international protection matters.

IP Australia+1

10. Costs and estimated processing time

IP Australia's published fee guidance lists the following indicative government fees. Fees can change, and professional fees are additional.

Additional fees may apply for excess claims, voluntary amendments and other procedural steps. The actual total cost of a biotechnology patent is often substantially higher when drafting, sequence analysis, experimental evidence and patent-attorney services are included.

IP Australia+1

IP Australia indicates that examination commonly takes around 12 months after the examination request, with expedited examination potentially reducing the wait to approximately eight weeks. These are indicative timeframes, not guarantees; total time to grant can be considerably longer.

IP Australia+1

11. Practical checklist before filing

Australian biotech patent filing checklist

0 of 10

Confirm inventors, ownership and assignment documents

Maintain confidentiality before filing

Search patent databases and scientific literature

Define the invention and its practical use

Prepare a complete technical description and supported claims

Check sequence-listing requirements

Assess whether a biological deposit is necessary

Review priority claims and international filing deadlines

Budget for examination, acceptance and renewal fees

Monitor examination reports and opposition deadlines

Reset checklist

12. Conclusion

Biotechnology patent filing in Australia requires more than submitting a scientific discovery to IP Australia. Applicants must identify a legally patentable invention, establish entitlement, prepare an enabling specification, address any biological deposit or sequence disclosure requirements, and manage examination and opposition deadlines.

The central lesson from D'Arcy v Myriad Genetics Inc is that isolation alone does not guarantee patentability when the essential claimed subject matter is naturally occurring genetic information. Successful applications should carefully distinguish the technical contribution from the discovery itself and ensure that the claims are supported by the disclosed invention.

For official guidance, consult the current Patents Act 1990 on the Federal Register of Legislation, IP Australia's biological inventions guidance, and its standard patent application procedure.

This is a general educational overview, not legal advice. Biotechnology patentability is highly dependent on the precise claims, technical disclosure and filing history. A registered Australian patent attorney should review a commercially important application before filing.